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Abstract Statins have anti-inflammatory and immuno-
modulatory properties in addition to lipid-lowering effects.
The present study evaluated the effect of atorvastatin added
to interferon beta-1b in multiple sclerosis (MS) in a mul-
ticenter, randomized, parallel-group, rater-blinded study
performed in eight Swiss hospitals. Seventy-seven patients
with relapsing-remitting MS started interferon beta-1b
every other day. After 3 months, they were randomized 1:1
to receive atorvastatin 40 mg/day or not in addition to
interferon beta-1b until month 15. The primary endpoint
was the proportion of patients with new lesions on
T2-weighted images at month 15 compared to baseline at
month three. At study end, the proportion of patients with
new lesions on T2-weighted images was equal in both
groups (odds ratio 1.14; 95 % CI 0.36–3.56; p = 0.81). All
predefined secondary endpoints including number of new
lesions and total lesion volume on T2-weighted images,
total number of new Gd-enhancing lesions on T1-weighted
images, total brain volume, volume of grey matter, volume
of white matter, EDSS, MSFC, relapse rate, time to first
relapse, number of relapse-free patients and neutralizing
antibodies did not show any significant differences (all
p values[0.1). Transient elevations of liver enzymes were
more frequent with atorvastatin (p = 0.02). In conclusion,
atorvastatin 40 mg/day in addition to interferon beta-1b did
not have a beneficial effect on relapsing-remitting MS
compared to interferon beta-1b monotherapy over a
12-month period.
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Introduction
Statins are lipid-lowering drugs inhibiting the 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA-) reductase, the
main regulatory enzyme of cholesterol biosynthesis. In
addition, statins have anti-inflammatory and immunomod-
ulatory properties independent of their cholesterol-lower-
ing effects [1].
Multiple sclerosis (MS) is a chronic inflammatory dis-
order of the central nervous system involving autoimmune
mechanisms [2]. Some years ago, interest into statins for
treatment of MS arose. Statins improve the course of
experimental allergic encephalomyelitis (EAE), an animal
model of MS [3–6]. Other experimental studies suggest a
negative impact of statins on oligodendrocytes and myelin
formation with impaired remyelination [7, 8]. Several
clinical studies of different statins in different dosages
given alone or in combination with interferon beta (IFNB)
for relapsing-remitting MS (RRMS) yielded beneficial,
harmful, or no effects as summarized in Table 1, whereas
the largest trial of simvastatin as add-on therapy to inter-
feron beta-1a (SIMCOMBIN) showed no beneficial effect
[9–15]. However, to date, it is not clear whether statins
have a class effect in MS or other statins in addition to
disease modifying drugs might be beneficial or even
harmful.
In the SWiss Atorvastatin and Interferon Beta-1b trial in
MS (SWABIMS) we evaluated the efficacy, safety, and
tolerability of atorvastatin 40 mg per os (p.o.) daily and
subcutaneous (s.c.) interferon beta-1b (IFNB-1b) every
other day (e.o.d) compared to monotherapy with s.c. IFNB-
1b e.o.d., an established therapy for RRMS [16].
Materials and methods
Study design
SWABIMS was a multi-center, randomized, parallel-
group, rater-blinded study in eight Swiss hospitals [17]. At
the beginning of the study (termed ‘‘baseline’’), all patients
started IFNB-1b (Betaferon/Betaseron, Bayer Schering
Pharma) for 3 months (termed ‘‘monotherapy phase’’). At
month three (termed ‘‘baseline at month three’’), they were
Table 1 Overview of clinical studies evaluating the combination of IFNB and statins in RRMS
Study type Patients Allocation IFNB Statin Primary endpoint/results
Paul et al.
[10]
Open-label
baseline-to-
treatment
trial
RRMS
(n = 41)
IFNB ? statin
(n = 16)
Statin (n = 25)
IFNB-1a
22 lg
t.i.w. or
IFNB-1b
e.o.d.
Atorvastatin
80 mg/day
Trend towards reduction of
Gd-enhancing lesions with
IFNB ? atorvastatin (p = 0.060)
Birnbaum
et al. [12]
Double-blind,
placebo-
controlled
trial
RRMS
(n = 26)
IFNB ? placebo
(n = 9)
IFNB ? statin
(n = 17)
IFNB-1a
44 lg
t.i.w.
Atorvastatin
80 mg/day
(n = 10) or
40 mg
(n = 7)
Increased MRI and clinical disease
activity with atorvastatin (p = 0.019)
Rudick
et al. [13]
Post hoc
analysis
RRMS
(n = 582)
IFNB (n = 542)
IFNB ? statin
(n = 40)
IFNB-1a
30 lg
once
weekly
Atorvastatin or
simvastatin
No difference in annualized relapse rate
and secondary endpoints
Lanzillo
et al. [14]
Longitudinal
controlled
trial
RRMS
(n = 45)
IFNB (n = 24)
IFNB ? statin
(n = 21)
IFNB-1a
44 lg s.c.
t.i.w.
Atorvastatin
20 mg/day
Fewer Gd-enhancing lesions versus
baseline (p = 0.007) and fewer relapses
versus the two pre-randomization years
(p \ 0.001) with atorvastatin
Togha
et al. [11]
Double-blind,
randomized
controlled
trial
RRMS
(n = 80)
IFNB ? placebo
(n = 38)
IFNB ? simvastatin
(n = 42)
IFNB-1a
30 lg
once
weekly
Simvastatin
40 mg/day
Lower relapse rate with simvastatin
(p = 0.01)
So¨rensen
et al. [15]
Placebo-
controlled
randomized
trial
RRMS
(n = 307)
IFNB ? statin
(n = 151)
IFNB ? placebo
(n = 156)
IFNB-1a
30 lg
once
weekly
Simvastatin
80 mg/day
No difference in annualized relapse rate
and secondary endpoints
SWABIMS Randomized
controlled
trial
RRMS
(n = 76)
IFNB ? statin
(n = 38)
IFNB (n = 38)
IFNB-1b
e.o.d.
Atorvastatin
40 mg/day
No difference of patients with new T2-
lesions and in secondary endpoints
n number, IFNB interferon beta, t.i.w. three times per week, e.o.d. every other day
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randomized 1:1 to receive atorvastatin 40 mg/day or not in
addition to IFNB-1b for another 12 months (termed ‘‘ran-
domized phase’’) (Fig. 1).
For the primary endpoint and all clinical and radiolog-
ical secondary endpoints, data at month 15 were compared
to data at baseline at month three before randomization to
atorvastatin or not.
Randomization was performed centrally by the clinical
research organization (CRO) after baseline visit in four-block
size, according to the randomization list (atorvastatin ‘‘yes’’
or ‘‘no’’) generated with ‘‘RANCODE Professional 3.6’’ [18].
Patients and treating physicians were aware, whether
atorvastatin was added. Placebo was not dispensed.
Examining physicians scoring disability [Expanded Dis-
ability Status Scale (EDSS); Multiple Sclerosis Functional
Composite (MSFC)] and neuroradiologists evaluating
magnetic resonance images (MR) were blinded to treat-
ment assignments [19, 20].
Atorvastatin was chosen because of its potent anti-
inflammatory and immunomodulatory properties and
favorable safety and pharmacokinetic profile [21–23].
Statins may cause dose-dependent elevation of hepatic
enzymes [24]. Therefore, the use of atorvastatin 40 mg/day
in combination with the potentially also hepatotoxic IFNB-
1b was reasonable, especially since the optimal immuno-
modulatory dose of statins in MS is unknown.
Each patient had to provide written informed consent
prior to study entry. The study was conducted in accor-
dance with the International Conference on Harmonisation
Guidelines for Good Clinical Practice (1996) and the
Declaration of Helsinki (2006), and was approved by the
local ethics committees and Swissmedic [25, 26]. The trial
Fig. 1 Enrollment, allocation,
and follow-up of patients
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Registration Identifier is 2005DR2119 (Swissmedic) and
NCT00942591 (clinicaltrials.gov).
Patients
Patients with RRMS according to the 2005 McDonald’s
criteria and disease duration [3 months, at least one
relapse in the past 2 years, C three lesions on spinal or
brain-MR or both, baseline EDSS score from 0 to 3.5
(inclusive), and age from 18 to 55 years were enrolled.
Main exclusion criteria were primary or secondary
progressive MS, clinically isolated syndrome (CIS), pre-
vious therapy with monoclonal antibodies, mitoxantrone,
other cytotoxic or immunosuppressive drugs, and IFNB or
glatiramer acetate within the last 12 months.
Study endpoints
The primary endpoint was the proportion of patients with
new lesions on T2-weighted MR images at month 15
compared to baseline at month three.
Secondary endpoints were the number of new lesions on
T2-weighted images, change in total lesion volume on
T2-weighted images (burden of disease), total number of
new gadolinium (Gd-)-enhancing lesions on T1-weighted
images, changes in total brain volume, volume of grey
matter and volume of white matter, clinical disease pro-
gression (EDSS, MSFC), relapse rate, time to first relapse,
number of relapse-free patients, and neutralizing antibodies
(NAbs).
Adverse events (AE), laboratory data, vital signs and
concomitant medication were analyzed as safety variables.
Study procedures
IFNB-1b was started at a dose of 0.0625 mg e.o.d. and then
increased weekly by 0.0625 to 0.25 mg e.o.d for the
baseline phase of 3 months.
At month three, atorvastatin 40 mg/day was given to
patients randomized to the atorvastatin/IFNB-1b group for
12 months. The other patients continued with IFNB-1b
monotherapy for the whole study period.
Regular visits were performed at month one, three, four,
six, nine, 12, and 15 for the assessment of EDSS, MSFC,
NAbs, laboratory tests, MR, and efficacy and safety end-
points. Atorvastatin use was controlled by counting the
returned tablets at visits at months six, nine, and 15. A
patient was considered as compliant when he took at least
80 % of all atorvastatin tablets.
A relapse was defined as a newly appearing objective
neurological abnormality in the absence of fever or known
infection, lasting for at least 24 h and occurring at least
30 days after a preceding clinical event, correlating with
the patient’s reported symptoms and increasing the total
EDSS score or at least one of the functional systems of the
EDSS score. Fatigue, mental, and/or vegetative symptoms
were not classified as relapse.
Relapses were treated within 7 days with intravenous
methylprednisolone 500 mg/day for 5 days followed by
tapering-out with oral prednisolone.
MR scans were acquired on 1.5-Tesla scanners at
screening, months three, nine, and 15. The MR protocol
included T1-weighted axial spin-echo, T1-weighted sagittal
3D MPRAGE, axial dual-echo, i.e., proton-density,
T2-weighted turbo-spin-echo images and axial T1-weighted
spin-echo images after intravenous Gd injection.
MR scans were assessed centrally by two neuroradiol-
ogists at the Institute of Diagnostic and Interventional
Neuroradiology of the University of Bern [27, 28]. A T2
lesion was defined as an area of increased signal on both
the proton-density and the T2-weighted images. Dis-
agreeing interpretations were discussed among the neuro-
radiologists to reach consensus. The image processing was
performed with an algorithm enabling semi-automatic
volumetry [29].
Laboratory analyses except NAbs were performed by
Viollier AG. Atorvastatin was reduced to 20 mg/day in
case of a more than threefold increase and stopped in case
of more than fivefold increase of transaminases. After-
wards liver enzymes were controlled regularly and ator-
vastatin was continued when transaminases were below a
threefold increase.
NAbs were assessed at the Ospedale San Luigi, Orbas-
sano, Italy. The cytopathic effect assay was used as rec-
ommended by the World Health Organization [30]. Data
from the neutralization assay were reported as reciprocal of
the highest dilution of serum inducing 50 % neutralization.
The neutralization titer was calculated according to Kaw-
ade’s formula and expressed in laboratory units (LU). A
concentration of [20 LU/ml was considered positive [31].
Patients with one or more NAb-positive titers were defined
NAb-positive. Two centers did not collect NAbs, explain-
ing the lower numbers of individuals for this analysis.
Statistical analysis
SAS version 9.2 was used for all statistical analyses. To
obtain a power of 84 % to detect the difference between the
monotherapy group proportion, p1, of 0.610 and the
combination therapy group proportion, p2, of 0.910 with a
0.05 two-sided significance level in the Fisher’s exact test,
a sample size of 38 patients in each group was needed [32].
All patients who took at least one dose of study medication
and had at least one follow-up observation were analyzed
[Full Analysis Set (FAS)]. Missing data because of drop-
outs on the primary endpoint were replaced with MR data
2404 J Neurol (2012) 259:2401–2413
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from the last available examination, which was month nine
in all drop-outs. The same approach was used for other
efficacy endpoints. Missing values for other parameters
were treated as missing, except for severity and relation-
ship of AEs to study drugs, which was regarded as severe
and related to study drug.
Categorical data were described by frequency and per-
centage, continuous data by mean, standard deviation,
minimum, 1st quartile, median, 3rd quartile, and maxi-
mum. Hypothesis tests were carried out with a a-level of
0.05, two-sided. All inferential analyses were presented by
p values, point estimations and two-sided 95 % CI for
treatment differences. If the assumption of normality in the
linear models was not fulfilled, transformations of the data
or non-parametric approaches like the Wilcoxon signed-
rank test were used.
Differences between treatment groups at baseline were
tested using t test or Fisher’s exact test depending on the
distribution of the data.
The primary efficacy variable was the proportion of
patients with new T2 lesions at month 15 compared to
baseline at month three. Based on a logistic regression
model with the factors treatment and gender and the
covariates number of T2 lesions, number of Gd-enhancing
lesions, EDSS, relapse rate and time since MS diagnosis at
baseline at month three, the two-sided hypothesis of
equality between the two treatments was tested at an
a-level of 0.05. The results were presented as odds ratios
and the associated two-sided 95 % CI and p values. Fur-
thermore, a Fisher’s exact test for proportions was executed
to test for the unadjusted treatment effect.
Secondary efficacy variables were analyzed with
covariance, logistic regression models, or Fisher’s exact
test depending on the distribution. Time to first relapse was
analyzed with non-parametric methods for failure time data
(Wilcoxon test) and illustrated by a Kaplan–Meier plot.
Assessments of safety and tolerability variables were
presented by treatment group. AEs were summarized for
each treatment group by presenting the number and per-
centage of subjects having an event, the number and per-
centage of event in each system organ class and preferred
term, as well as severity and relationship to the study drug.
Any medication taken during the study was classified as
concomitant and coded using WHO-Drug 2007.1.
Results
The recruitment period was from May 2005 to December
2008, in which 88 patients were screened. Seventy-seven
patients fulfilled the study criteria and were included and
all of them were randomized at baseline at month three.
None of them had previous immunomodulatory or
immunosuppressive therapy. Five patients dropped out,
four in the atorvastatin/IFNB-1b and one in the IFNB-1b
group (Fig. 1). The EDSS score of one patient at screening
was too high as we realized only in retrospect. This patient
was excluded from the efficacy analysis (76 patients) but
remained in the safety analysis (77 patients). The atorva-
statin compliance was[80 % in the randomized phase. All
relapses were treated with steroids as defined above.
Demographic and baseline characteristics are presented
in Table 2. Patients of the atorvastatin/IFNB-1b group
were younger than patients of the IFNB-1b group. Gender,
ethnic origin, height, weight, and BMI were well matched.
Mean duration since diagnosis of MS, relapse rate
within the past 2 years, number and volume of lesions on
T2-weighted images, number and volume of Gd-enhancing
lesions on T1-weighted images, brain volume and EDSS
and MSFC scores at baseline did not differ significantly.
During the monotherapy phase, both groups developed
equally regarding all endpoints with no statistically sig-
nificant differences. At baseline at month three, there was a
trend towards a higher disease activity of the atorvastatin/
IFNB-1b group caused by the distribution at baseline
and the decline of the arithmetic average, median, and
variability.
The results for the primary and secondary efficacy
variables are given in Table 3. The proportion of patients
with new lesions on T2-weighted images at month 15
compared to baseline at month three was not different
according to the logistic regression model (p = 0.81). The
adjusted odds ratio (OR) and the 95 % CI for the treatment
difference of atorvastatin/IFNB-1b versus IFNB-1b were
1.14 and 0.36–3.56. To test the unadjusted treatment dif-
ferences, an exploratory analysis with Fisher’s exact test
was performed. Again, no significant difference was
detected (p = 0.64).
The predefined secondary endpoints number of new
lesions and total lesion volume on T2-weighted images,
total number of Gd-enhancing lesions on T1-weighted
images, total brain volume, volume of grey matter, volume
of white matter, EDSS, MSFC (including subscores),
relapse rate, and number of relapse-free patients did not
show any significant differences between the treatment
groups at month 15 (all p values [0.1). In individual
patients, data on study endpoints were missing because of a
variety of reasons, e.g., movement artifacts during single
MR sequences or incomplete data collection at visits. Two
centers did not provide adequate MRI data for the analysis
of total brain volume and grey and white matter volumes.
This explains the lower numbers of individuals in some
endpoints.
The logistic regression model regarding the primary
endpoint with new T2 lesions as dependent variable and
treatment, number of T2 lesions, number of Gd-enhancing
J Neurol (2012) 259:2401–2413 2405
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Table 2 Patient characteristics
Characteristics Atorvastatin/interferon beta-1b Interferon beta-1b p value
n = 38 n = 38
Demographic characteristics at screening/baseline
Age (years)
Mean ± SD 30.5 ± 7.9 35.7 ± 7.95 0.0032
Median (range) 28 (19 to 50) 36 (18 to 49)
Gender (n, %)
Male 17 (44.7 %) 15 (39.5 %)
Female 21 (55.3 %) 23 (60.5 %) 0.82
Caucasian (n, %) 38 (100 %) 38 (100 %)
Height (cm)
Mean ± SD 171.8 ± 8.30 170.6 ± 9.75
Median (range) 170 (156 to 191) 166.5 (157 to 192) 0.34
Weight (kg)
Mean ± SD 71.42 ± 14.98 72.48 ± 18.18
Median (range) 70 (43 to 106) 69 (44.5 to 124) 0.91
BMI (kg/m2)
Mean ± SD 24.15 ± 4.61 24.74 ± 5.3
Median (range) 23.39 (16.4 to 34.6) 23.07 (17.2 to 45.5) 0.70
MR findings at baseline at month 3
No. of T2 hyperintense lesions
n 36 37
Mean ± SD 27.3 ± 24.24 21.2 ± 19.24
Median (range) 21 (1 to 113) 14 (2 to 80) 0.19
Total volume of T2 hyperintense lesions (cm3)
n 36 37
Mean ± SD 3.5 ± 3.24 2.7 ± 2.68
Median (range) 2.96 (0.3 to 12.4) 1.69 (0.1 to 9.6) 0.22
No. of GD-enhancing lesions on T1-weighted images
n 37 38
Mean ± SD 1.1 ± 2.9 0.3 ± 0.64
Median (range) 0 (0 to 17) 0 (0 to 2) 0.08
Total volume of GD-enhancing lesions on T1-weighted images (cm3)
n 37 38
Mean ± SD 0.09 ± 0.21 0.02 ± 0.07
Median (range) 0 (0 to 1.1) 0 (0 to 0.4) 0.043
Total brain volume (cm3)
n 28 31
Mean ± SD 1,476.8 ± 161.9 1,418.6 ± 151.97
Median (range) 1,431.6 (1,209 to 1,898) 1,411.4 (1,129 to 1,782) 0.16
Volume of grey matter (cm3)
n 28 31
Mean ± SD 734.6 ± 68.09 708.7 ± 73.29
Median (range) 728.97 (620 to 867) 694 (587 to 880) 0.14
Volume of white matter (cm3)
n 28 31
Mean ± SD 434.5 ± 46.29 416.3 ± 65.2
Median (range) 428.5 (366 to 573) 427.1 (270 to 544) 0.21
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T1 lesions, volume of Gd-enhancing T1 lesions, relapse
rate, EDSS, time since MS diagnosis, age and gender at
baseline as influencing variables showed that age
(p = 0.04), number of Gd-enhancing T1 lesions (p = 0.02)
and number of T2 lesions (p = 0.01) at baseline had a
significant influence on the number of new T2 lesions
whereas treatment did not (p = 0.72). Furthermore, age
had a significant influence on the dependent variables of
relapse rate, total brain volume, and volume of white
matter whereas treatment did not.
NAb were evaluated in 60 of 77 patients (29 in the
atorvastatin/IFNB-1b group; 31 in the IFNB-1b group).
Sixteen patients turned NAb-positive in the atorvastatin/
IFNB-1b group and 11 patients in the IFNB-1b group
(p = 0.12). Neither the time of occurrence of NAb nor the
titers differed between the groups. Five of 11 patients in the
IFNB-1b group and two of 16 patients in the atorvastatin/
IFNB-1b group turned from NAb-positive to NAb-negative
during the study (p = 0.22).
The time to first relapse failed to prove significance in
the Wilcoxon test as well (p = 0.16). The median (50 %
quartile) time to first relapse could be calculated for the
atorvastatin/IFNB-1b group, but because of an insufficient
number of relapses not for the IFNB-1b group. The 25 %
quartiles (atorvastatin/IFNB-1b group 100 days; IFNB-1b
group 220 days) showed a non-significant shorter time to
the next relapse in the atorvastatin/IFNB-1b group.
The Cox regression model with the time to first relapse
as dependent variable and treatment, gender, number of T2
lesions, number of Gd-enhancing lesions, EDSS, relapse
rate, time since diagnosis, age and volume of T1 lesions as
influencing variables showed that age (p = 0.04) had a
significant influence on the time to first relapse whereas
treatment did not (p = 0.33).
Details on AEs by system organ class are given in
Table 4. During the monotherapy and randomized phases,
any AEs including serious and severe AEs occurred equally
in both groups. During the randomized phase, AEs were
more frequently related to the study drug in the atorva-
statin/IFNB-1b group.
In the randomized phase, elevated liver enzymes
occurred more often in the atorvastatin/IFNB-1b group
(p = 0.02). All other AEs were equally distributed.
Because of elevated liver enzymes, atorvastatin was tran-
siently reduced in six patients (mean 3.1 month) and
stopped for good in three patients 3.6 month on average
before study termination. In the IFNB-1b group, IFNB was
stopped temporarily in one patient.
In the atorvastatin/IFNB-1b group, AEs were classified
as mild in 16 (41 %), moderate in 14 (35.9 %), and severe
in one (2.6 %) subject. The severe AE was an influenza-
like illness. There was one serious AE (SAE), a lumbar
herniated disk. In the IFNB-1b group, AEs were classified
as mild in ten (26.3 %), moderate in 12 (31.6 %), and
Table 2 continued
Characteristics Atorvastatin/interferon beta-1b Interferon beta-1b p value
n = 38 n = 38
Clinical characteristics
MS duration at screening (years)
Mean ± SD 0.88 ± 2.86 0.86 ± 1.46 0.20
No. of relapses in the past 2 years before screening (n, %)
n 38 38
1 12 (31.6 %) 11 (28.9 %)
2 19 (50.0 %) 24 (63.2 %)
3 3 (7.9 %) 3 (7.9 %)
4 3 (7.9 %) 0 (0 %)
8 1 (2.6 %) 0 (0 %) 0.38
EDSS at baseline at month 3
n 38 38
Mean ± SD 1.8 ± 1.0 1.9 ± 1.1
Median (range) 2 (0 to 3.5) 2 (0 to 4) 0.37
MSFC at baseline at month 3
n 38 38
Mean ± SD 0.26 ± 0.49 0.18 ± 0.46
Median (range) 0.38 (-1.2 to 1.0) 0.18 (-0.9 to 1.0) 0.26
n number of patients, SD standard deviation, EDSS Expanded Disability Status Scale: MSFC Multiple Sclerosis Functional Composite, BMI body
mass index: ns no significant difference
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Table 3 Efficacy endpoints (FAS, n = 76)
Endpoint Atorvastatin/interferon-beta-1b Interferon-beta-1b p value
n = 38 n = 38
MR endpoints
Proportion of patients with new lesions on T2-weighted images, baseline at month 3 to month 15 (n %)
n 37 37
Yes 18 (47.37) 15 (39.47)
No 19 (50.0) 22 (57.89)
Odds ratio for atorvastatin/IFNB-1b versus IFNB-1b (95 % CI) 1.14 (0.366 to 3.56) 0.81
No. of new lesions on T2-weighted images, baseline at month 3 to month 15
n 36 37
Mean ± SD 3.3 ± 6.81 1.7 ± 4.05
Median (range) 0 (0 to 36) 0 (0 to 21)
Treatment difference for atorvastatin /IFNB-1b vs. IFNB-1b (95 % CI) -0.45 (-2.12 to 1.22) 0.59
Change in lesion volume (cm3) on T2-weighted images, baseline at month 3 to month 15
n 36 37
Mean ± SD 0.4 ± 2.65 0.2 ± 1.26
Median (range) 0 (-4 to 12) 0 (-1 to 5)
Treatment difference for atorvastatin /IFNB-1b vs. IFNB-1b (95 % CI) -0.50 (-1.21 to 0.19) 0.15
Total number of Gd-enhancing T1 lesions at month 9 and 15
n 37 38
Mean ± SD 3.9 ± 12.89 2.2 ± 5.41
Median 0 (0 to 65) 0 (0 to 25)
Treatment difference for atorvastatin /IFNB-1b vs. IFNB-1b (95 % CI) -1.76 (-4.78 to 0.96) 0.20
Change of total brain volume (cm3), baseline at month 3 to month 15
n 27 31
Mean ± SD -13.7 ± 59.32 -4.9 ± 33.7
Median (range) -3.7 (-295 to 36) -2.7 (-108 to 115) 0.91
Change of grey matter volume (cm3), baseline at month 3 to month 15
n 27 31
Mean ± SD -4.0 ± 18.2 -5.8 ± 41.95
Median (range) -0.5 (-58 to 31) -1.5 (-185 to 101) 0.21
Change of white matter volume (cm3), baseline at month 3 to month 15
n 27 31
Mean ± SD 0.9 ± 12.35 2.5 ± 39.24
Median (range) 1.5 (-28 to 26) -0.7 (-141 to 126) 0.78
Clinical endpoints
Change in EDSS score, baseline at month 3 to month 15
n 37 38
Mean ± SD 0.03 ± 0.90 0.17 ± 0.5
Median (range) 0 (-2 to 2) 0 (-2 to 2)
Least squares means for effect treatment (95 % CI) -0.11 (-0.54 to 0.32) 0.61
Change in MSFC score, baseline at month 3 to month 15
n 37 38
Mean ± SD 0.1 ± 0.27 0.1 ± 0.32
Median (range) 0.1 (0–1) 0.1 (-1 to 1)
Least squares means for effect treatment (95 % CI) -0.08 (-0.22 to 0.06) 0.24
Relapse, baseline at month 3 to month 15
n 38 38
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severe in two (5.3 %) subjects. The severe AEs were der-
mal herpes zoster and lumbar disk prolapse. Blood lipid
levels were similar at baseline at month three. Total and
low-density lipoprotein cholesterol decreased significantly
(p \ 0.0001) in the atorvastatin/IFNB-1b group compared
to the IFNB-1b group.
Discussion
Atorvastatin 40 mg added to IFNB-1b did not have any
beneficial effect on RRMS compared to IFNB-1b mono-
therapy over a period of 12 months. There were no sig-
nificant differences in the primary or secondary endpoints
between the two treatment groups.
Patients in the atorvastatin/IFNB-1b group were signif-
icantly younger, showed a trend towards higher disease
activity at baseline, and had significantly larger volumes of
Gd-enhancing lesions on T1-weighted images. A multiple
regression analysis showed that this imbalance at baseline,
and not the different treatment, was responsible for the
trends towards a higher disease activity of the atorvastatin/
IFNB-1b group at study end. Therefore, a negative effect of
atorvastatin cannot be concluded.
The combination of atorvastatin and IFNB-1b was
well tolerated and did not cause unexpected or severe
side-effects. However, elevated liver enzymes without
clinical symptoms occurred more often in the atorva-
statin/IFNB-1b group and led to a temporary reduction or
stop of atorvastatin in several patients. It cannot be
distinguished whether atorvastatin alone or the combi-
nation accounted for the elevated liver enzymes. Liver
enzymes normalized and atorvastatin could be continued
at full dosage in most patients. However, in three
patients, atorvastatin had to be stopped. Other AEs were
similar in both groups.
SWABIMS also addressed the question, whether ator-
vastatin had an impact on NAbs against INFB-1b. There
was a trend towards a higher prevalence and longer per-
sistence of NAbs in the atorvastatin/IFNB-1b group that
might indicate a negative effect of atorvastatin on NAb
formation. However, for the moment, this does not have
clinical implications.
The results of SWABIMS suggest that atorvastatin
40 mg added to IFNB-1b has no beneficial effect on
RRMS. The results of SWABIMS are similar to the results
of the SIMCOMBIN trial, the largest randomized trial that
added simvastatin to IFNB-1a in RRMS as well as to a post
hoc analysis of the SENTINEL trial. None of the two
studies showed any beneficial effect of statins [13, 15].
Therefore, neither atorvastatin nor simvastatin are to be
recommended as an add-on therapy to IFNB.
Table 3 continued
Endpoint Atorvastatin/interferon-beta-1b Interferon-beta-1b p value
n = 38 n = 38
Relapse-free (n, %)
No 18 (43.4 %) 13 (34.2 %)
Yes 20 (52.6 %) 25 (65.8 %)
Odds ratio of atorvastatin/IFNB-1b versus IFNB-1b (95 % CI) 0.65 (0.22 to 1.90) 0.43
No. of relapses
Total number 28 23
Mean ± SD 0.7 ± 0.98 0.6 ± 1.05
Median (range) 0 (0 to 4) 0 (0 to 4) 0.63
Time to first relapse (25 % quartiles estimates)
Mean ± SD 220.3 ± 18.08 284 ± 18.73 0.16
Neutralizing antibodies (NAb)
NAb-positive (n, %)
n 29 31
No 13 (44.8 %) 20 (64.5 %)
Yes 16 (55.2 %) 11 (35.5 %) 0.12
Change from NAb-positive to NAb-negative
n 29 31
No 14/16 (87.5 %) 6/11 (54.5 %)
Yes 2/16 (12.5 %) 5/11 (45.5 %) 0.22
Treatment differences were calculated using ANCOVA
n number of patients with data, SD standard deviation, EDSS Expanded Disability Status Scale, MSFC Multiple Sclerosis Functional Composite
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Table 4 Adverse events by system organ class MedDRA (FAS, n = 77)
Events n (%) Atorvastatin/ Interferon-beta-1b Interferon-beta-1b p value
(n = 39) (n = 38)
Total number of adverse events 101 89
Adverse events (AE) by number of subjects
Overall adverse event 36 (92.3 %) 27 (71.1 %) ns
Monotherapy phase
Any AE 25 (64.1 %) 21 (55.3 %) ns
Any serious AE 0 (0 %) 0 (0 %) ns
Any severe AE 0 (0 %) 2 (5.3 %) ns
Any AE related to study drug 17 (43.6 %) 17 (44.7 %) ns
Any AE leading to discontinuation of study drug 0 (0 %) 2 (5.3 %) ns
Randomized phase
Any AE 31 (79.5 %) 24 (63.2 %) ns
Any serious AE 0 (0 %) 1 (2.6 %) ns
Any severe AE 1 (2.6 %) 2 (5.3 %) ns
Any AE related to study drug 22 (56.4 %) 12 (31.6 %) 0.02
Any AE leading to discontinuation of study drug 0 (0 %) 1 (2.6 %) ns
Most frequently ([5 %) reported AE during the randomized phase by number of subjects
Eye disorders
Glaucoma 0 (0 %) 2 (5.3 %) ns
Gastrointestinal disorders
Diarrhea 2 (5.1 %) 2 (5.3 %) ns
Nausea 3 (7.7 %) 1 (2.6 %) ns
General disorders/administration site conditions
Fatigue 2 (5.1 %) 4 (10.5 %) ns
Influenza-like illness 4 (10.3 %) 5 (13.2 %) ns
Pyrexia 0 (0 %) 2 (5.3 %) ns
Infections and infestations
Influenza 3 (7.7 %) 3 (7.9 %) ns
Nasopharyngitis 5 (12.8 %) 2 (5.3 %) ns
Injury, poisoning, and procedural complications
Joint injury 2 (5.1 %) 0 (0 %) ns
Abnormal laboratory values
Elevated liver enzymes 9 (23.1 %) 2 (5.3 %) 0.02
Musculoskeletal and connective tissue disorders
Muscle spasms 2 (5.1 %) 4 (10.5 %) ns
Myalgia 3 (7.7 %) 0 (0 %) ns
Nervous system disorders
Headache 3 (7.7 %) 4 (10.5 %) ns
Muscular weakness 0 (0 %) 2 (5.3 %) ns
Paraesthesia 1 (2.6 %) 2 (5.3 %) ns
Psychiatric disorders
Depression 2 (5.1 %) 2 (5.3 %) ns
Renal and urinary disorders
Bladder disorder 0 (0 %) 2 (5.3 %) ns
Respiratory, thoracic and mediastinal disorders
Epistaxis 0 (0 %) 2 (5.3 %) ns
Pharyngolaryngeal pain 2 (5.1 %) 1 (2.6 %) ns
Skin and subcutaneous tissue disorders
Acne 2 (5.1 %) 1 (2.6 %) ns
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A minimal beneficial or harmful effect of other combi-
nations of statins and IFNB cannot be definitely excluded
yet. Other trials have supported positive or negative effects
of statins, but this would have to be proved in larger studies
(Table 1). A marked effect, however, seems unlikely
because of the results of the largest trial (SIMCOMBIN),
our SWABIMS study, and the comparable immunomodu-
latory properties of the different statins in experimental
studies [6, 33].
The rationale to combine immunomodulatory drugs with
different mechanisms of action is to obtain additive anti-
inflammatory effects. This is the case for statins and IFNB-
1b in vitro. Both inhibit the proliferation of stimulated
peripheral blood mononuclear cells, reduce the expression
of activation-induced adhesion molecules on T cells,
modify the T helper 1/T helper 2 cytokine balance, reduce
matrix metalloproteinases (MMP) -9, and downregulate
chemokine receptors on both B and T cells [33]. However,
combination therapies may lead to antagonistic effects as
well. Besides anti-inflammatory effects, statins also show
proinflammatory properties such as interferon-c produc-
tion, inhibit STAT1 phosphorylation, which is an important
signaling pathway for IFNB, and antagonize the inhibitory
effect of IFNB on the proteolytic activity on MMP-2 and
MMP-9 [33–35]. The antagonistic mechanisms could
potentially explain the negative results of studies combin-
ing IFNB and statins.
Multiple sclerosis patients with vascular risk factors and
vascular disease have a more rapid disability progression
than MS patients without [36, 37]. Therefore, vascular risk
factors and diseases should be treated as rigorously as in
non-MS patients. Provided that liver enzymes are moni-
tored, SWABIMS suggests that atorvastatin 40 mg can be
used for vascular prevention in MS patients who need a
lipid-lowering therapy.
There are limitations of the SWABIMS study. It was a
multi-center, randomized, parallel-group, rater-blinded
trial, but not placebo-controlled. At the time of study
planning and initiation, an identical placebo was not
available. Therefore, we chose a prospective randomized
rater-blinded end-point study design. Nevertheless, the
evaluating clinicians and neuroradiologists assessing MR
endpoints were blinded. Other limitations are the sample
size and that we chose a surrogate marker instead of a
clinical endpoint as primary endpoint. However, sample
size calculations with the limited data of statins in MS
available in 2005 indicated that the patient numbers of
SWABIMS could give meaningful results with a primary
MR endpoint. Another limitation might be the dose of
atorvastatin. In vascular disease, higher doses of atorva-
statin are more effective than lower doses. However, the
optimal immunomodulatory dosage is unknown and it is
not certain that higher doses yield higher efficacy. There-
fore, and for safety reasons, we chose a daily dose of
40 mg of atorvastatin.
In conclusion, atorvastatin 40 mg/day in addition to
IFNB-1b did not have any beneficial effect on RRMS com-
pared to IFNB-1b monotherapy over a period of 12 months.
Therefore, adding atorvastatin 40 mg/day to IFNB-1b seems
to be no treatment option for patients with RRMS.
Acknowledgments This work was supported by grants from Bayer
Schering Pharma (Switzerland) and Pfizer (Switzerland). The sponsor
was the Department of Neurology of the University Hospital Bern,
Switzerland.
Conflicts of interest Dr. Kamm has received honoraria for lectures
from Biogen-Dompe´, Novartis, Bayer, Teva and Pfizer. Dr. Humpert
has received honoraria for lectures from Biogen-Dompe´, Merck-
Serono and Novartis. Dr. Donati has received honoraria for consulting
from Merck-Serono, Pfizer and Teva. Dr. Findling, Dr. von Bredow,
Ms. Burren, Dr. Schwegler, Dr. Scho¨tt, Drs. Mu¨ller, Dr. Slotboom,
Dr. Naegelin, and Prof. Tettenborn have no competing interests. Prof.
Goebels received honoraria for lectures from, served as principal
investigator, member of steering committees, or member of advisory
boards in clinical trials sponsored by, or has had consulting agree-
ments over the past 5 years with Bayer-Schering, Biogen-Idec,
Merck-Serono, Novartis, Sanofi-Aventis, and other companies
involved in the development of MS therapeutics, received research
support by the Swiss National Research Foundation, the National
Center for Competence in Research Neural Plasticity and Repair,
Biogen-Idec, Merck-Serono SA Geneva, the Swiss Multiple Sclerosis
Society, the 3R Research Foundation Switzerland, and the Koetser
Foundation for Brain Research. Prof. Kappos received research sup-
port from the Swiss National Research Foundation, the Swiss MS
Society, and from the Gianni Rubatto Foundation (Zurich); has served
on scientific advisory boards and his Department at the University
Hospital Basel has received research support from Acorda Thera-
peutics Inc., Actelion Pharmaceuticals Ltd, Abbott, AstraZeneca,
Bayhill Therapeutics, Bayer Schering Pharma, Biogen Idec, Boeh-
ringer Ingelheim, Centocor Ortho Biotech Inc., Eisai Inc., Genzyme
Corporation, GlaxoSmithKline, The Immune Response Corporation,
Table 4 continued
Events n (%) Atorvastatin/ Interferon-beta-1b Interferon-beta-1b p value
(n = 39) (n = 38)
Dry skin 1 (2.6 %) 2 (5.3 %) ns
Eczema 2 (5.1 %) 0 (0 %) ns
AE adverse event, n number, ns no significant difference
J Neurol (2012) 259:2401–2413 2411
123
MediciNova, Inc., Neurocrine Biosciences, Novartis, Sanofi-Aventis,
Merck Serono, Roche, Teva Pharmaceutical Industries Ltd., UCB,
and Wyeth. Prof. Mattle has received honoraria for lectures and
consulting from Bayer-Schering, Biogen-Dompe´, Merck-Serono,
TEVA, Sanofi-Aventis, Novartis, and Pfizer.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Appendix
SWABIMS study group
Neurology
Aarau: G Schwegler, M Leichtle, B Kieser; Basel: L
Kappos, L Achtnichts, Y Naegelin; Bern: H P Mattle, C P
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Blatter, I Beiser; Biel: F Donati, M Alfaro, M Braun-
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mann, P Wicki; St. Gallen: B Tettenborn, N Putzki, S
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Clinical research organization
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Safety monitoring board
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